Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)
Status
Completed
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Details and patient eligibility
About
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
Enrollment
3,409 patients
Sex
All
Ages
12 to 70 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- existing diagnosis of ADPKD by modified-Ravine criteria
- Total kidney volume >= 300 cc/m height by ultrasound or >= 250 cc/m height by MRI
Exclusion criteria
- Current or expected (within the next six months) interventions for the treatment of ADPKD affecting kidney volume
Trial design
3,409 participants in 1 patient group
No treatment
Trial contacts and locations
266
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems